Moving erlotinib from formulary tier 3 to tier 2 resulted in lower copayments and higher treatment persistence among lung cancer patients.
Carolina M. Reyes, PhD
Advertisement
Articles by Carolina M. Reyes, PhD
Erlotinib may confer an economic advantage for payers over docetaxel and pemetrexed for second-line treatment of lung cancer because of lower costs.
Advertisement
Latest Updated Articles
- Costs Associated With Second-Line Therapies for Lung Cancer
Published: February 2nd 2011 | Updated:
- Lung Cancer: Copayments and Behavior Following Erlotinib Formulary Tier Change
Published: November 13th 2012 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Evolving Mortality Trends in Heart Failure and Vascular Disease: The Critical Role of Pharmacists in Addressing Cardiovascular Risk
2
Targeting Mitochondrial Metabolism in Heart Failure: From Genetic Drivers to Fuel Modulation Therapies
3
SGLT2 Inhibitors Linked to Lower Atrial Fibrillation Risk, Recurrence
4
Frequent Continuous Glucose Monitoring Linked to Greater HbA1C Reductions in Adults With T2D
5
